Gregory Schwartz
Concepts (589)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 74 | 2025 | 293 | 15.970 |
Why?
| | Anticholesteremic Agents | 55 | 2026 | 152 | 12.630 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 57 | 2025 | 439 | 7.760 |
Why?
| | Lipoprotein(a) | 22 | 2025 | 68 | 7.460 |
Why?
| | Antibodies, Monoclonal, Humanized | 47 | 2025 | 985 | 6.430 |
Why?
| | Cholesterol, LDL | 53 | 2026 | 358 | 6.370 |
Why?
| | Myocardial Infarction | 45 | 2026 | 1209 | 4.790 |
Why?
| | Cardiovascular Diseases | 41 | 2026 | 2168 | 4.380 |
Why?
| | Proprotein Convertase 9 | 29 | 2025 | 87 | 3.730 |
Why?
| | Coronary Disease | 16 | 2020 | 383 | 3.040 |
Why?
| | Angina, Unstable | 19 | 2019 | 82 | 2.750 |
Why?
| | Heptanoic Acids | 23 | 2016 | 67 | 2.590 |
Why?
| | Cholesterol, HDL | 13 | 2020 | 200 | 2.590 |
Why?
| | Diabetes Mellitus, Type 2 | 23 | 2025 | 2583 | 2.510 |
Why?
| | Dyslipidemias | 9 | 2025 | 181 | 2.460 |
Why?
| | Sulfhydryl Compounds | 10 | 2020 | 189 | 2.440 |
Why?
| | Hypercholesterolemia | 11 | 2023 | 92 | 2.410 |
Why?
| | Pyrroles | 23 | 2016 | 217 | 2.390 |
Why?
| | Stroke | 32 | 2026 | 1256 | 2.260 |
Why?
| | Quinazolinones | 7 | 2021 | 19 | 2.110 |
Why?
| | Serine Proteinase Inhibitors | 6 | 2025 | 51 | 2.100 |
Why?
| | Atherosclerosis | 12 | 2026 | 409 | 1.590 |
Why?
| | Myocardial Ischemia | 17 | 2018 | 285 | 1.570 |
Why?
| | Thiazolidinediones | 10 | 2017 | 138 | 1.540 |
Why?
| | Secondary Prevention | 11 | 2019 | 254 | 1.530 |
Why?
| | Double-Blind Method | 43 | 2025 | 2029 | 1.520 |
Why?
| | Cholesterol | 12 | 2022 | 406 | 1.510 |
Why?
| | Treatment Outcome | 68 | 2026 | 11679 | 1.430 |
Why?
| | Oxazoles | 9 | 2022 | 48 | 1.360 |
Why?
| | Esters | 9 | 2020 | 78 | 1.350 |
Why?
| | Amides | 9 | 2020 | 101 | 1.330 |
Why?
| | Thiophenes | 9 | 2022 | 128 | 1.290 |
Why?
| | Cholesterol Ester Transfer Proteins | 5 | 2016 | 22 | 1.280 |
Why?
| | Hypoglycemic Agents | 18 | 2024 | 1387 | 1.230 |
Why?
| | Risk Factors | 45 | 2024 | 10779 | 1.220 |
Why?
| | Aged | 83 | 2026 | 25913 | 1.210 |
Why?
| | Myocardial Contraction | 14 | 2013 | 298 | 1.140 |
Why?
| | Middle Aged | 87 | 2026 | 35875 | 1.130 |
Why?
| | Ventricular Fibrillation | 3 | 2017 | 64 | 1.130 |
Why?
| | Humans | 176 | 2026 | 144759 | 1.130 |
Why?
| | Swine | 35 | 2023 | 833 | 1.100 |
Why?
| | Risk Assessment | 21 | 2025 | 3671 | 1.090 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 741 | 1.080 |
Why?
| | C-Reactive Protein | 11 | 2022 | 416 | 1.080 |
Why?
| | Insulin Resistance | 10 | 2018 | 1241 | 1.060 |
Why?
| | Myocardium | 23 | 2004 | 939 | 1.010 |
Why?
| | Antibodies, Monoclonal | 7 | 2023 | 1519 | 1.010 |
Why?
| | Metabolic Syndrome | 4 | 2013 | 354 | 1.000 |
Why?
| | Diabetic Angiopathies | 2 | 2019 | 263 | 1.000 |
Why?
| | Male | 110 | 2026 | 72315 | 0.980 |
Why?
| | Female | 116 | 2026 | 78271 | 0.920 |
Why?
| | Myocardial Reperfusion Injury | 5 | 2013 | 137 | 0.910 |
Why?
| | Ischemic Attack, Transient | 6 | 2018 | 71 | 0.900 |
Why?
| | Heart | 10 | 2009 | 636 | 0.870 |
Why?
| | PPAR gamma | 6 | 2022 | 176 | 0.860 |
Why?
| | Lipoproteins, HDL | 4 | 2019 | 101 | 0.850 |
Why?
| | Proteins | 3 | 2020 | 1021 | 0.850 |
Why?
| | RNA, Small Interfering | 11 | 2026 | 635 | 0.840 |
Why?
| | Hyperlipoproteinemia Type II | 4 | 2026 | 32 | 0.830 |
Why?
| | Proprotein Convertases | 2 | 2014 | 16 | 0.810 |
Why?
| | Peripheral Arterial Disease | 3 | 2020 | 503 | 0.810 |
Why?
| | Triglycerides | 5 | 2024 | 520 | 0.770 |
Why?
| | Biomarkers | 24 | 2025 | 4271 | 0.770 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2026 | 653 | 0.700 |
Why?
| | Fatty Acids, Nonesterified | 4 | 2018 | 158 | 0.700 |
Why?
| | Randomized Controlled Trials as Topic | 19 | 2024 | 1720 | 0.700 |
Why?
| | Time Factors | 22 | 2025 | 7173 | 0.680 |
Why?
| | Patient Admission | 2 | 2021 | 218 | 0.670 |
Why?
| | Insulin | 7 | 2021 | 2507 | 0.660 |
Why?
| | Coronary Circulation | 18 | 2004 | 136 | 0.660 |
Why?
| | Cardiovascular Agents | 4 | 2021 | 164 | 0.640 |
Why?
| | Molecular Targeted Therapy | 2 | 2014 | 432 | 0.640 |
Why?
| | Hospitalization | 5 | 2019 | 2433 | 0.610 |
Why?
| | Recurrence | 11 | 2021 | 1135 | 0.600 |
Why?
| | Energy Metabolism | 13 | 2004 | 935 | 0.570 |
Why?
| | Swine, Miniature | 3 | 2013 | 89 | 0.550 |
Why?
| | Adiponectin | 2 | 2018 | 244 | 0.550 |
Why?
| | Lipid Metabolism | 2 | 2014 | 527 | 0.540 |
Why?
| | Venous Thrombosis | 1 | 2020 | 194 | 0.530 |
Why?
| | Brain Ischemia | 5 | 2022 | 358 | 0.530 |
Why?
| | Ezetimibe | 4 | 2023 | 24 | 0.530 |
Why?
| | Heart Arrest | 4 | 2017 | 407 | 0.520 |
Why?
| | Aldosterone | 1 | 2017 | 43 | 0.500 |
Why?
| | Rosuvastatin Calcium | 4 | 2022 | 21 | 0.500 |
Why?
| | Cardiovascular System | 1 | 2018 | 137 | 0.490 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 324 | 0.460 |
Why?
| | Phospholipids | 4 | 2025 | 213 | 0.450 |
Why?
| | Arteriosclerosis | 2 | 2014 | 84 | 0.440 |
Why?
| | Patient Readmission | 2 | 2021 | 758 | 0.430 |
Why?
| | Drug Therapy, Combination | 6 | 2020 | 1047 | 0.420 |
Why?
| | Adenosine Triphosphate | 14 | 2017 | 498 | 0.420 |
Why?
| | Magnetic Resonance Spectroscopy | 17 | 2019 | 630 | 0.400 |
Why?
| | Metformin | 1 | 2017 | 318 | 0.400 |
Why?
| | Diabetes Complications | 3 | 2021 | 222 | 0.390 |
Why?
| | Apolipoproteins | 4 | 2025 | 38 | 0.390 |
Why?
| | Animals | 49 | 2023 | 38058 | 0.380 |
Why?
| | Heart Failure | 10 | 2026 | 2323 | 0.380 |
Why?
| | Phosphocreatine | 13 | 1995 | 44 | 0.380 |
Why?
| | Phosphates | 7 | 2024 | 180 | 0.370 |
Why?
| | Ventricular Function, Left | 9 | 2004 | 541 | 0.360 |
Why?
| | Veterans | 3 | 2023 | 1603 | 0.360 |
Why?
| | Blood Pressure | 11 | 2012 | 1769 | 0.360 |
Why?
| | Hemodynamics | 11 | 2007 | 1121 | 0.360 |
Why?
| | Proportional Hazards Models | 9 | 2019 | 1325 | 0.360 |
Why?
| | Coronary Vessels | 8 | 2012 | 251 | 0.350 |
Why?
| | Obesity | 3 | 2024 | 3077 | 0.350 |
Why?
| | Uncertainty | 1 | 2012 | 144 | 0.350 |
Why?
| | Dietary Fats | 2 | 2013 | 314 | 0.340 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 550 | 0.330 |
Why?
| | Drug Administration Schedule | 8 | 2019 | 779 | 0.330 |
Why?
| | Follow-Up Studies | 11 | 2023 | 5408 | 0.320 |
Why?
| | Glucose | 5 | 2020 | 1047 | 0.320 |
Why?
| | Systole | 7 | 2001 | 178 | 0.320 |
Why?
| | Fluorobenzenes | 2 | 2014 | 17 | 0.320 |
Why?
| | Reperfusion Injury | 2 | 2005 | 300 | 0.310 |
Why?
| | Research Design | 3 | 2009 | 1135 | 0.310 |
Why?
| | Risk | 9 | 2018 | 911 | 0.310 |
Why?
| | Phospholipases A2, Secretory | 4 | 2014 | 14 | 0.310 |
Why?
| | Diastole | 5 | 2001 | 143 | 0.290 |
Why?
| | Ischemia | 1 | 2012 | 421 | 0.290 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2007 | 248 | 0.280 |
Why?
| | KATP Channels | 1 | 2008 | 17 | 0.270 |
Why?
| | Surgical Procedures, Operative | 4 | 2017 | 270 | 0.270 |
Why?
| | Apolipoproteins B | 5 | 2022 | 47 | 0.270 |
Why?
| | Cohort Studies | 6 | 2023 | 5960 | 0.270 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2024 | 117 | 0.260 |
Why?
| | Chromans | 3 | 2004 | 23 | 0.260 |
Why?
| | Acute Disease | 9 | 2012 | 1030 | 0.260 |
Why?
| | Hypolipidemic Agents | 3 | 2022 | 88 | 0.260 |
Why?
| | Peptide Fragments | 4 | 2024 | 699 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2019 | 2027 | 0.260 |
Why?
| | Mortality | 3 | 2017 | 375 | 0.260 |
Why?
| | Survival Analysis | 7 | 2018 | 1382 | 0.260 |
Why?
| | Incidence | 7 | 2022 | 2879 | 0.250 |
Why?
| | Veterans Health | 2 | 2020 | 189 | 0.250 |
Why?
| | Apolipoprotein B-100 | 2 | 2025 | 13 | 0.250 |
Why?
| | Potassium | 2 | 2014 | 152 | 0.250 |
Why?
| | Sodium | 2 | 2020 | 197 | 0.250 |
Why?
| | Cholecalciferol | 1 | 2007 | 60 | 0.250 |
Why?
| | Diet | 3 | 2025 | 1273 | 0.240 |
Why?
| | Pyrimidines | 2 | 2014 | 532 | 0.240 |
Why?
| | Prognosis | 6 | 2024 | 4282 | 0.240 |
Why?
| | Sulfonamides | 2 | 2014 | 580 | 0.240 |
Why?
| | Subtilisins | 2 | 2023 | 9 | 0.240 |
Why?
| | Hyperlipoproteinemia Type III | 1 | 2025 | 4 | 0.230 |
Why?
| | Fenofibrate | 1 | 2005 | 28 | 0.230 |
Why?
| | Endpoint Determination | 1 | 2026 | 83 | 0.230 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 112 | 0.230 |
Why?
| | Dobutamine | 5 | 2000 | 24 | 0.220 |
Why?
| | Acetates | 3 | 2019 | 80 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2013 | 250 | 0.220 |
Why?
| | Myelodysplastic Syndromes | 1 | 2007 | 147 | 0.220 |
Why?
| | Oxygen Consumption | 8 | 2000 | 724 | 0.220 |
Why?
| | Quinolines | 1 | 2026 | 193 | 0.220 |
Why?
| | Apolipoprotein A-I | 2 | 2018 | 39 | 0.220 |
Why?
| | Disease Models, Animal | 8 | 2013 | 4557 | 0.220 |
Why?
| | Cardiotonic Agents | 3 | 2005 | 95 | 0.220 |
Why?
| | Blood Glucose | 6 | 2024 | 2327 | 0.210 |
Why?
| | Natriuretic Peptide, Brain | 3 | 2024 | 111 | 0.210 |
Why?
| | Prediabetic State | 2 | 2020 | 245 | 0.210 |
Why?
| | Predictive Value of Tests | 6 | 2025 | 2115 | 0.210 |
Why?
| | Lanthanum | 1 | 2024 | 13 | 0.210 |
Why?
| | Morbidity | 5 | 2017 | 323 | 0.210 |
Why?
| | Hyperemia | 3 | 1991 | 49 | 0.210 |
Why?
| | Syndrome | 6 | 2007 | 380 | 0.200 |
Why?
| | Cause of Death | 5 | 2017 | 471 | 0.200 |
Why?
| | Injections, Subcutaneous | 2 | 2024 | 164 | 0.200 |
Why?
| | Thiazoles | 2 | 2003 | 135 | 0.200 |
Why?
| | Phosphorylation | 3 | 2013 | 1732 | 0.200 |
Why?
| | Isoproterenol | 3 | 1998 | 97 | 0.190 |
Why?
| | Serine Endopeptidases | 2 | 2014 | 128 | 0.190 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 4 | 2017 | 17 | 0.190 |
Why?
| | Blood Vessels | 1 | 2024 | 171 | 0.190 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2019 | 77 | 0.190 |
Why?
| | Genes, Bacterial | 1 | 2023 | 166 | 0.190 |
Why?
| | Residence Characteristics | 3 | 2016 | 377 | 0.180 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2026 | 370 | 0.180 |
Why?
| | Calcitriol | 2 | 2003 | 58 | 0.180 |
Why?
| | Lipids | 3 | 2024 | 710 | 0.180 |
Why?
| | Multicenter Studies as Topic | 3 | 2019 | 405 | 0.180 |
Why?
| | Prostatic Neoplasms | 5 | 2003 | 974 | 0.180 |
Why?
| | Calcifediol | 2 | 2000 | 31 | 0.180 |
Why?
| | Livestock | 2 | 2023 | 11 | 0.180 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 55 | 0.170 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 209 | 0.170 |
Why?
| | Diacetyl | 1 | 2001 | 7 | 0.170 |
Why?
| | PPAR alpha | 4 | 2022 | 54 | 0.170 |
Why?
| | Indoles | 3 | 2019 | 501 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2026 | 365 | 0.170 |
Why?
| | Propensity Score | 2 | 2021 | 367 | 0.170 |
Why?
| | Muscles | 1 | 2022 | 333 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 634 | 0.170 |
Why?
| | Mental Status and Dementia Tests | 1 | 2021 | 26 | 0.170 |
Why?
| | Oxidative Stress | 2 | 2025 | 1339 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2000 | 919 | 0.160 |
Why?
| | Cytokines | 2 | 2005 | 2061 | 0.160 |
Why?
| | Myocardial Reperfusion | 1 | 2000 | 59 | 0.160 |
Why?
| | Cataract | 1 | 2023 | 238 | 0.160 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 88 | 0.160 |
Why?
| | Calpain | 2 | 2012 | 61 | 0.160 |
Why?
| | Lipoproteins, LDL | 2 | 2014 | 119 | 0.150 |
Why?
| | Coronary Artery Bypass | 2 | 2019 | 268 | 0.150 |
Why?
| | Matrix Metalloproteinases | 1 | 2000 | 98 | 0.150 |
Why?
| | Cadmium | 1 | 2000 | 69 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 780 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 266 | 0.150 |
Why?
| | Oncogenes | 1 | 2000 | 119 | 0.150 |
Why?
| | Perioperative Care | 2 | 2017 | 231 | 0.150 |
Why?
| | Renin-Angiotensin System | 1 | 2019 | 78 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2013 | 436 | 0.140 |
Why?
| | Aged, 80 and over | 9 | 2026 | 8265 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 145 | 0.140 |
Why?
| | Adrenergic beta-Agonists | 1 | 1998 | 92 | 0.140 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 60 | 0.140 |
Why?
| | Early Termination of Clinical Trials | 2 | 2015 | 18 | 0.140 |
Why?
| | Immunoturbidimetry | 1 | 2018 | 1 | 0.140 |
Why?
| | United States | 7 | 2023 | 15966 | 0.140 |
Why?
| | Carotid Artery Diseases | 1 | 2018 | 69 | 0.140 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 202 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 226 | 0.140 |
Why?
| | Collagen | 1 | 2000 | 456 | 0.130 |
Why?
| | American Heart Association | 1 | 2019 | 350 | 0.130 |
Why?
| | Environment | 2 | 2016 | 305 | 0.130 |
Why?
| | Citrate (si)-Synthase | 1 | 2017 | 57 | 0.130 |
Why?
| | Pharmacogenetics | 2 | 2016 | 172 | 0.130 |
Why?
| | Prostate | 1 | 1998 | 158 | 0.130 |
Why?
| | Microalgae | 1 | 2016 | 10 | 0.130 |
Why?
| | Ponds | 1 | 2016 | 17 | 0.130 |
Why?
| | Transcription Factors | 2 | 2016 | 1741 | 0.130 |
Why?
| | Hypertension, Pulmonary | 3 | 2012 | 1980 | 0.120 |
Why?
| | Australia | 4 | 2019 | 286 | 0.120 |
Why?
| | Administration, Intravenous | 1 | 2017 | 170 | 0.120 |
Why?
| | Waste Disposal, Fluid | 1 | 2016 | 53 | 0.120 |
Why?
| | HIV Long Terminal Repeat | 1 | 2016 | 11 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2019 | 543 | 0.120 |
Why?
| | Global Health | 2 | 2017 | 401 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 173 | 0.120 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 25 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1953 | 0.120 |
Why?
| | Inflammation Mediators | 2 | 2013 | 509 | 0.120 |
Why?
| | Simvastatin | 2 | 2015 | 60 | 0.120 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2016 | 55 | 0.120 |
Why?
| | Adult | 15 | 2026 | 40449 | 0.120 |
Why?
| | Lipoproteins | 2 | 2014 | 169 | 0.120 |
Why?
| | Inflammation | 6 | 2016 | 2878 | 0.120 |
Why?
| | Signal Transduction | 1 | 2009 | 5226 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 684 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 190 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1053 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2019 | 2919 | 0.110 |
Why?
| | Heart Ventricles | 6 | 2012 | 760 | 0.110 |
Why?
| | Glomerular Filtration Rate | 3 | 2026 | 760 | 0.110 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2012 | 142 | 0.110 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2015 | 13 | 0.110 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 497 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1370 | 0.110 |
Why?
| | Vasodilation | 2 | 2013 | 523 | 0.110 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2015 | 35 | 0.110 |
Why?
| | Smoking | 2 | 2000 | 1472 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2019 | 1030 | 0.110 |
Why?
| | Wireless Technology | 1 | 2014 | 18 | 0.110 |
Why?
| | Bacteria | 2 | 2023 | 889 | 0.110 |
Why?
| | Linkage Disequilibrium | 1 | 2015 | 246 | 0.100 |
Why?
| | Homeostasis | 1 | 2018 | 640 | 0.100 |
Why?
| | Serum Amyloid A Protein | 3 | 2013 | 32 | 0.100 |
Why?
| | Transistors, Electronic | 1 | 2014 | 9 | 0.100 |
Why?
| | Stents | 1 | 2018 | 556 | 0.100 |
Why?
| | Seawater | 1 | 2014 | 31 | 0.100 |
Why?
| | Ions | 1 | 2014 | 71 | 0.100 |
Why?
| | Disease Progression | 4 | 2018 | 2847 | 0.100 |
Why?
| | Heart Rate | 5 | 2001 | 855 | 0.100 |
Why?
| | Fresh Water | 1 | 2014 | 56 | 0.100 |
Why?
| | Phospholipases A | 1 | 2014 | 98 | 0.100 |
Why?
| | Metals, Heavy | 1 | 2014 | 31 | 0.100 |
Why?
| | Fasting | 1 | 2015 | 277 | 0.100 |
Why?
| | Mendelian Randomization Analysis | 1 | 2013 | 55 | 0.100 |
Why?
| | Endovascular Procedures | 1 | 2018 | 384 | 0.100 |
Why?
| | Commerce | 1 | 2014 | 79 | 0.100 |
Why?
| | Acyl Coenzyme A | 1 | 2013 | 31 | 0.100 |
Why?
| | Heart Function Tests | 1 | 2013 | 59 | 0.090 |
Why?
| | Ultraviolet Rays | 2 | 1992 | 388 | 0.090 |
Why?
| | Hydroxy Acids | 1 | 2012 | 4 | 0.090 |
Why?
| | Ventricular Function, Right | 1 | 1995 | 297 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 289 | 0.090 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2012 | 35 | 0.090 |
Why?
| | Talin | 1 | 2012 | 10 | 0.090 |
Why?
| | Decanoic Acids | 1 | 2012 | 14 | 0.090 |
Why?
| | Cardiolipins | 1 | 2013 | 82 | 0.090 |
Why?
| | Glyburide | 1 | 2012 | 31 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 204 | 0.090 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 47 | 0.090 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2012 | 24 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 612 | 0.090 |
Why?
| | North America | 3 | 2019 | 310 | 0.090 |
Why?
| | Biosensing Techniques | 1 | 2014 | 139 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2019 | 3604 | 0.090 |
Why?
| | Europe | 3 | 2019 | 412 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2018 | 17066 | 0.090 |
Why?
| | Keto Acids | 3 | 2019 | 13 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1560 | 0.090 |
Why?
| | Oxidation-Reduction | 4 | 2025 | 1087 | 0.090 |
Why?
| | Hypertension | 1 | 2000 | 1263 | 0.080 |
Why?
| | DNA | 2 | 2013 | 1463 | 0.080 |
Why?
| | Arteries | 1 | 2013 | 259 | 0.080 |
Why?
| | Prospective Studies | 2 | 2021 | 7990 | 0.080 |
Why?
| | Tissue Plasminogen Activator | 2 | 2013 | 244 | 0.080 |
Why?
| | Genetic Variation | 1 | 2016 | 983 | 0.080 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 310 | 0.080 |
Why?
| | Fractures, Bone | 1 | 2016 | 414 | 0.080 |
Why?
| | Manure | 2 | 2023 | 10 | 0.080 |
Why?
| | Prejudice | 1 | 2011 | 60 | 0.080 |
Why?
| | Myocardial Revascularization | 3 | 2017 | 85 | 0.080 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 230 | 0.080 |
Why?
| | Electrocardiography | 3 | 2011 | 662 | 0.080 |
Why?
| | Phosphorus | 5 | 1995 | 99 | 0.080 |
Why?
| | Down-Regulation | 2 | 2024 | 627 | 0.080 |
Why?
| | HIV-1 | 1 | 2016 | 896 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2608 | 0.080 |
Why?
| | United States Department of Veterans Affairs | 3 | 2016 | 768 | 0.080 |
Why?
| | Polymers | 1 | 2014 | 499 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2015 | 2832 | 0.070 |
Why?
| | Age Factors | 3 | 2011 | 3333 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 1990 | 186 | 0.070 |
Why?
| | Critical Care | 1 | 2014 | 695 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1511 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 701 | 0.070 |
Why?
| | Vascular Diseases | 2 | 2022 | 251 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2014 | 684 | 0.070 |
Why?
| | Ventricular Pressure | 1 | 2007 | 52 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2875 | 0.070 |
Why?
| | Equipment Design | 3 | 2014 | 530 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1098 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 380 | 0.070 |
Why?
| | Vitamin D | 3 | 2000 | 400 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1821 | 0.060 |
Why?
| | Angiomatosis | 1 | 2006 | 5 | 0.060 |
Why?
| | Ultrasonography, Interventional | 2 | 2018 | 160 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 14 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 965 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 621 | 0.060 |
Why?
| | Survival Rate | 1 | 2011 | 2089 | 0.060 |
Why?
| | Lactic Acid | 2 | 1998 | 302 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 474 | 0.060 |
Why?
| | Angina Pectoris | 2 | 2004 | 75 | 0.060 |
Why?
| | Ultrasonography | 1 | 2009 | 770 | 0.060 |
Why?
| | Cerebrovascular Disorders | 2 | 2017 | 103 | 0.060 |
Why?
| | Apolipoproteins E | 1 | 2025 | 94 | 0.060 |
Why?
| | Liver | 2 | 2024 | 1887 | 0.050 |
Why?
| | Chronic Disease | 1 | 2011 | 1813 | 0.050 |
Why?
| | alpha-Tocopherol | 1 | 2004 | 32 | 0.050 |
Why?
| | Sus scrofa | 1 | 2004 | 64 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2025 | 266 | 0.050 |
Why?
| | Linear Models | 2 | 2013 | 854 | 0.050 |
Why?
| | Heterozygote | 1 | 2025 | 315 | 0.050 |
Why?
| | Arterial Occlusive Diseases | 2 | 1982 | 90 | 0.050 |
Why?
| | Vegetables | 1 | 2025 | 170 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 72 | 0.050 |
Why?
| | CD40 Ligand | 1 | 2004 | 40 | 0.050 |
Why?
| | Least-Squares Analysis | 1 | 2004 | 76 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 847 | 0.050 |
Why?
| | Economics, Pharmaceutical | 1 | 2003 | 10 | 0.050 |
Why?
| | Muscular Diseases | 1 | 2004 | 108 | 0.050 |
Why?
| | Ergocalciferols | 1 | 2003 | 14 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2003 | 919 | 0.050 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2003 | 43 | 0.050 |
Why?
| | Regional Blood Flow | 3 | 1996 | 514 | 0.050 |
Why?
| | Comorbidity | 2 | 2019 | 1658 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 267 | 0.050 |
Why?
| | Lactates | 2 | 1994 | 83 | 0.050 |
Why?
| | beta-Lactams | 1 | 2023 | 32 | 0.050 |
Why?
| | Death | 2 | 2019 | 130 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 114 | 0.050 |
Why?
| | Creatine Kinase | 1 | 2022 | 72 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2022 | 62 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1539 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 221 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2023 | 196 | 0.040 |
Why?
| | Verapamil | 1 | 2001 | 37 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.040 |
Why?
| | Organ Preservation Solutions | 1 | 2001 | 47 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 206 | 0.040 |
Why?
| | Antioxidants | 1 | 2004 | 549 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2000 | 27 | 0.040 |
Why?
| | Goals | 1 | 2022 | 183 | 0.040 |
Why?
| | Ventricular Dysfunction | 1 | 2000 | 16 | 0.040 |
Why?
| | Myocardial Stunning | 1 | 2000 | 4 | 0.040 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2000 | 19 | 0.040 |
Why?
| | Collagenases | 1 | 2000 | 22 | 0.040 |
Why?
| | Hexamethonium | 1 | 2000 | 5 | 0.040 |
Why?
| | Vascular Stiffness | 1 | 2025 | 486 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 288 | 0.040 |
Why?
| | Atropine | 1 | 2000 | 37 | 0.040 |
Why?
| | Soil Microbiology | 1 | 2023 | 218 | 0.040 |
Why?
| | Dilatation, Pathologic | 1 | 2000 | 62 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2003 | 361 | 0.040 |
Why?
| | Louisiana | 1 | 2000 | 28 | 0.040 |
Why?
| | Interleukin-6 | 3 | 2013 | 780 | 0.040 |
Why?
| | Dipeptides | 2 | 2012 | 57 | 0.040 |
Why?
| | Health Care Costs | 1 | 2003 | 427 | 0.040 |
Why?
| | Occupations | 1 | 2000 | 51 | 0.040 |
Why?
| | Cell Line | 2 | 2016 | 2882 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 25 | 0.040 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2000 | 132 | 0.040 |
Why?
| | Pericardium | 1 | 2000 | 62 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 392 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1886 | 0.040 |
Why?
| | Blood Chemical Analysis | 1 | 2020 | 109 | 0.040 |
Why?
| | Phospholipase A2 Inhibitors | 1 | 2019 | 3 | 0.040 |
Why?
| | New Zealand | 1 | 2019 | 54 | 0.040 |
Why?
| | Insulin Antagonists | 1 | 1998 | 6 | 0.040 |
Why?
| | Ventricular Function | 1 | 1999 | 57 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 2117 | 0.040 |
Why?
| | Antigens, CD | 1 | 2022 | 555 | 0.040 |
Why?
| | Hormone Antagonists | 1 | 1998 | 34 | 0.040 |
Why?
| | Hungary | 1 | 2018 | 5 | 0.040 |
Why?
| | Somatostatin | 1 | 1998 | 51 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 192 | 0.040 |
Why?
| | Israel | 1 | 2018 | 46 | 0.040 |
Why?
| | Infusion Pumps | 1 | 2018 | 32 | 0.040 |
Why?
| | Pulmonary Artery | 2 | 2006 | 1134 | 0.040 |
Why?
| | Netherlands | 1 | 2018 | 82 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 1999 | 415 | 0.040 |
Why?
| | India | 1 | 2019 | 218 | 0.040 |
Why?
| | Drug Combinations | 1 | 2000 | 390 | 0.040 |
Why?
| | Elasticity | 1 | 1999 | 184 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2024 | 790 | 0.030 |
Why?
| | Florida | 1 | 1998 | 117 | 0.030 |
Why?
| | Protective Factors | 1 | 2018 | 99 | 0.030 |
Why?
| | Drug Interactions | 1 | 2019 | 398 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1837 | 0.030 |
Why?
| | Sex Factors | 1 | 2024 | 2112 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 413 | 0.030 |
Why?
| | Drug Industry | 1 | 2017 | 49 | 0.030 |
Why?
| | Selection Bias | 1 | 2017 | 38 | 0.030 |
Why?
| | Catheterization | 1 | 1997 | 183 | 0.030 |
Why?
| | Poverty Areas | 1 | 2016 | 42 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 194 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 1997 | 133 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 529 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 96 | 0.030 |
Why?
| | Erythrocytes | 1 | 2022 | 757 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 33 | 0.030 |
Why?
| | Rural Health | 1 | 2016 | 87 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2000 | 560 | 0.030 |
Why?
| | Drug Discovery | 1 | 2017 | 155 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.030 |
Why?
| | Viral Tropism | 1 | 2016 | 36 | 0.030 |
Why?
| | Receptors, CCR5 | 1 | 2016 | 60 | 0.030 |
Why?
| | Albuminuria | 1 | 2017 | 190 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2016 | 91 | 0.030 |
Why?
| | Troponin | 2 | 2007 | 49 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2016 | 139 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 2009 | 284 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2004 | 1185 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1166 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 450 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2438 | 0.030 |
Why?
| | Myalgia | 1 | 2015 | 13 | 0.030 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 1996 | 157 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1406 | 0.030 |
Why?
| | Physicians | 1 | 2004 | 939 | 0.030 |
Why?
| | Creatinine | 1 | 2017 | 506 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2015 | 53 | 0.030 |
Why?
| | Electromagnetic Radiation | 1 | 2014 | 3 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 461 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 1996 | 163 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2015 | 75 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 268 | 0.030 |
Why?
| | Myositis | 1 | 2015 | 57 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1996 | 421 | 0.030 |
Why?
| | Lidocaine | 1 | 1994 | 54 | 0.030 |
Why?
| | Quality of Life | 1 | 2007 | 3185 | 0.030 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1994 | 29 | 0.030 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1995 | 124 | 0.030 |
Why?
| | Calibration | 1 | 2014 | 151 | 0.030 |
Why?
| | Adenosine | 2 | 1994 | 255 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 167 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1306 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1995 | 276 | 0.030 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2015 | 118 | 0.030 |
Why?
| | Semiconductors | 1 | 2014 | 38 | 0.030 |
Why?
| | Seasons | 1 | 2016 | 556 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 84 | 0.030 |
Why?
| | Stroke Volume | 1 | 1997 | 651 | 0.030 |
Why?
| | Pressure | 1 | 2014 | 225 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2000 | 1455 | 0.030 |
Why?
| | Mice | 3 | 2016 | 18339 | 0.020 |
Why?
| | NAD | 1 | 1994 | 81 | 0.020 |
Why?
| | Solutions | 1 | 2014 | 166 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 134 | 0.020 |
Why?
| | Mitochondria, Heart | 1 | 1994 | 102 | 0.020 |
Why?
| | Glycine | 1 | 1994 | 187 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2017 | 375 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 40 | 0.020 |
Why?
| | Perioperative Period | 1 | 2013 | 71 | 0.020 |
Why?
| | Materials Testing | 1 | 2014 | 354 | 0.020 |
Why?
| | Heparin | 1 | 1994 | 244 | 0.020 |
Why?
| | Binding Sites | 1 | 2016 | 1329 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 1994 | 210 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 1992 | 140 | 0.020 |
Why?
| | Immunoglobulin G | 2 | 2009 | 893 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2014 | 282 | 0.020 |
Why?
| | Actinin | 1 | 2012 | 12 | 0.020 |
Why?
| | Dogs | 3 | 1984 | 437 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1907 | 0.020 |
Why?
| | Weight Gain | 1 | 2016 | 556 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 1326 | 0.020 |
Why?
| | Mathematics | 1 | 1992 | 100 | 0.020 |
Why?
| | South Africa | 1 | 2013 | 261 | 0.020 |
Why?
| | Cardiac Output, Low | 1 | 1992 | 54 | 0.020 |
Why?
| | Cardiomyopathy, Dilated | 2 | 1992 | 359 | 0.020 |
Why?
| | Patient Selection | 1 | 1996 | 719 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 331 | 0.020 |
Why?
| | Vascular Resistance | 2 | 1984 | 367 | 0.020 |
Why?
| | Biopsy | 1 | 1995 | 1075 | 0.020 |
Why?
| | Reperfusion | 1 | 1991 | 54 | 0.020 |
Why?
| | Perfusion | 1 | 1992 | 250 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 769 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2011 | 78 | 0.020 |
Why?
| | Georgia | 1 | 2011 | 83 | 0.020 |
Why?
| | Constriction | 1 | 1990 | 47 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 1990 | 15 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5868 | 0.020 |
Why?
| | Anticoagulants | 1 | 1996 | 722 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1998 | 4154 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 983 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 879 | 0.020 |
Why?
| | Regression Analysis | 1 | 1992 | 1003 | 0.020 |
Why?
| | Cell Division | 2 | 2003 | 766 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 538 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2015 | 477 | 0.020 |
Why?
| | Autoantibodies | 2 | 2009 | 1501 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2145 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 93 | 0.020 |
Why?
| | Educational Status | 1 | 2011 | 467 | 0.020 |
Why?
| | Young Adult | 2 | 2016 | 14105 | 0.020 |
Why?
| | Thromboembolism | 1 | 2009 | 125 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1992 | 588 | 0.020 |
Why?
| | Spectrin | 1 | 2007 | 14 | 0.020 |
Why?
| | Desmin | 1 | 2007 | 24 | 0.020 |
Why?
| | Densitometry | 1 | 2007 | 37 | 0.020 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2007 | 33 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1486 | 0.020 |
Why?
| | Poverty | 1 | 2011 | 529 | 0.020 |
Why?
| | Heart Diseases | 1 | 1990 | 349 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2007 | 219 | 0.020 |
Why?
| | Kidney | 1 | 2014 | 1495 | 0.010 |
Why?
| | ROC Curve | 1 | 2007 | 614 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 307 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2007 | 477 | 0.010 |
Why?
| | Aminophylline | 1 | 1984 | 12 | 0.010 |
Why?
| | Vasomotor System | 1 | 1984 | 46 | 0.010 |
Why?
| | Solubility | 1 | 2004 | 242 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5992 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 2003 | 87 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2003 | 163 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2004 | 539 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1716 | 0.010 |
Why?
| | Odds Ratio | 1 | 2004 | 1075 | 0.010 |
Why?
| | Electrophysiology | 1 | 1982 | 218 | 0.010 |
Why?
| | Echocardiography | 2 | 1997 | 652 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 1187 | 0.010 |
Why?
| | Vascular Surgical Procedures | 1 | 2004 | 339 | 0.010 |
Why?
| | Mixed Function Oxygenases | 1 | 2000 | 49 | 0.010 |
Why?
| | Chemoprevention | 1 | 2000 | 90 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 2 | 1991 | 561 | 0.010 |
Why?
| | Adolescent | 2 | 2016 | 22428 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 983 | 0.010 |
Why?
| | Thorax | 1 | 1997 | 50 | 0.010 |
Why?
| | Phosphorus Isotopes | 1 | 1995 | 8 | 0.010 |
Why?
| | Infusions, Parenteral | 1 | 1994 | 41 | 0.010 |
Why?
| | Apoptosis | 1 | 2003 | 2430 | 0.010 |
Why?
| | Cardiac Pacing, Artificial | 1 | 1995 | 84 | 0.010 |
Why?
| | Basal Metabolism | 1 | 1994 | 62 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1995 | 388 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2002 | 1982 | 0.010 |
Why?
| | Glycolysis | 1 | 1995 | 339 | 0.010 |
Why?
| | Lung | 1 | 2006 | 4109 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1992 | 53 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2527 | 0.010 |
Why?
| | Diphosphoglyceric Acids | 1 | 1991 | 3 | 0.010 |
Why?
| | 2,3-Diphosphoglycerate | 1 | 1991 | 32 | 0.010 |
Why?
| | Radio Waves | 1 | 1991 | 28 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1990 | 174 | 0.000 |
Why?
| | Rats | 1 | 1997 | 5597 | 0.000 |
Why?
| | Theophylline | 1 | 1984 | 41 | 0.000 |
Why?
| | Heart Block | 1 | 1984 | 40 | 0.000 |
Why?
| | Oxygen | 1 | 1984 | 995 | 0.000 |
Why?
| | Magnetic Resonance Imaging | 1 | 1990 | 3863 | 0.000 |
Why?
|
|
Schwartz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|